

NCT ID	NCT03668431
Title	Dabrafenib + Trametinib + PDR001 In Colorectal Cancer
Phase	Phase 2
Date Added	2018-09-12
Location	Massachusetts, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Dabrafenib, PDR001, Trametinib, Mekinist, Tafinlar
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03667170
Title	KN035 for dMMR/MSI-H Advanced Solid Tumors
Phase	Phase 2
Date Added	2018-09-12
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd
NCT ID	NCT03658785
Title	Immunotherapy for the Treatment of Advanced Solid Tumor
Phase	Phase 1
Date Added	2018-09-05
Location	China
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	Aldesleukin, Cyclophosphamide, Fludarabine, TIL
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03657641
Title	Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer
Phase	Phase 1
Date Added	2018-09-05
Location	California, United States Florida, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Pembrolizumab, Regorafenib, Keytruda, Stivarga
Tags	MSS/ MMRp
NCT ID	NCT03650348
Title	PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
Phase	Phase 1
Date Added	2018-08-28

Location	California, United States Louisiana, United States New York, United States Ohio, United States Texas, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	PRS-343 in Combination with Atezolizumab, Tecentriq
Tags	MSS/ MMRp
NCT ID	NCT03638297
Title	PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer
Phase	Phase 2
Date Added	2018-08-20
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	PD-1 antibody + cox inhibitor
Tags	MSI-H/ MMRd
NCT ID	NCT03638206
Title	Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Phase	Phase 1/Phase 2
Date Added	2018-08-20
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	CAR-T cell immunotherapy
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03626922
Title	Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients
Phase	Phase 1
Date Added	2018-08-13
Location	Florida, United States Illinois, United States Michigan, United States Minnesota, United States Pennsylvania, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Dexamethasone, oxaliplatin, Pembrolizumab, Pemetrexed, Alimta, Eloxatin, Keytruda
Tags	MSS/ MMRp
NCT ID	NCT03608046
Title	Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer
Phase	Phase 2
Date Added	2018-07-31

Location	Belgium
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Avelumab, Cetuximab Injection, Irinotecan
Tags	MSS/ MMRp
NCT ID	NCT03600883
Title	A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreak 100)
Phase	Phase 1, Phase 2
Date Added	2018-07-26
Location	California, United States Colorado, United States Connecticut, United States Delaware, United States Florida, United States Georgia, United States Indiana, United States Maryland, United States Massachusetts, United States Michigan, United States Missouri, United States New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Australia Austria Belgium Brazil Canada France Germany Greece Hungary Japan Portugal Romania South Korea Spain Switzerland
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	Anti PD-1/L1, Midazolam, Sotorasib
Tags	MSS/ MMRp